SecBot SecBot
8-K ·Filed Nov 9, 2026

ABCL

AbCellera Biologics Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7d 8h ago SEC0001703057-26-000058
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Watch for ABCL635 late-stage development initiation in 2027 and 12-week/OLE data in early 2027; the Phase 2 efficacy data appear superior to approved NK3R antagonists, but the company remains pre-revenue on its own pipeline and the $200M raise adds dilution.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ABCL drug pipeline →

ABCL635

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
Phase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.
Next catalyst
None dated

What to watchThe next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$12.46
T+0 close · Nov 9, 2026 · via day close
Latest settled
−4.09%
T+1 · $11.95 · next T+5 in 6h
Vs SPY
−5.41%
α at T+1
Latest observation
−5.54%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $12.46entry
  2. T+1 · 6d ago −4.09%α −5.41% · $11.95
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbCellera reported Q3 2026 revenue of $10.6M (up 19% YoY from $9.0M) and a net loss of $40.8M ($0.13 per share), narrower than the $57.1M loss in Q3 2025. The company announced positive Phase 2 data for ABCL635 in menopausal hot flashes, completed a $200M equity offering, and ended the quarter with over $890M in available liquidity. No EPS or revenue consensus was provided, so no beat/miss rating is assigned.

Key Financial Metrics

EPS
−$0.13
Revenue
$10.6M
+18.8% YoY

Key Facts

  • Q3 2026 total revenue $10.6M vs $9.0M in Q3 2025 (+19% YoY)
  • Net loss $40.8M ($0.13 per share) vs $57.1M ($0.19) in Q3 2025
  • Positive top-line Phase 2 data for ABCL635 in menopausal vasomotor symptoms
  • Completed $200M offering of common shares and pre-funded warrants at $9.75 per share
  • Ended Q3 with over $790M in cash and marketable securities, over $890M total liquidity
  • Partner-led programs with downstreams declined to 34 from 44 at Dec 2025
  • R&D expenses $43.5M vs $55.0M in Q3 2025; SG&A $13.6M vs $25.0M
  • Year-to-date operating cash flow positive at $19.3M vs negative $96.5M in prior year

Financial Impact

Revenue up 19% YoY; net loss narrowed 29% YoY; cash position strengthened to $890M after $200M equity raise

revenuenet losscash and liquidity

Risk Factors

  • Pre-revenue biotech with no approved products; net loss continues
  • ABCL635 Phase 3 development and regulatory approval still years away
  • Partner-led pipeline declining (44 to 34 programs with downstreams)
  • Dilution from $200M equity offering (~20M shares at $9.75)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001703057-26-000058
Document: abcl-20261109.htm0001703057-26-000058
Document: a2026q3businessupdatenov.htm0001703057-26-000058
Document: 0001703057-26-000058-index-headers.html0001703057-26-000058
Document: 0001703057-26-000058-index.html0001703057-26-000058
Document: 0001703057-26-000058.txt0001703057-26-000058
8-K Data (Synthetic)0001703057-26-000058

Track record

16 reports on ABCL

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +127.09% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $11.63 Now $11.12 −4.39% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  3. Nov 13, 20263d ago Insider Cluster Bullish 4/10 Entry $11.49 Now $11.12 −3.22% settles Feb 11
  4. Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $12.46 Now $11.12 −10.75% settles Feb 8
  5. Aug 24, 202612w ago Insider Cluster Mixed 5/10 Entry $12.50 Now $11.12 −11.04% settles Nov 18
  6. Aug 18, 202612w ago Insider Cluster Bullish 5/10 Entry $11.12 to $11.95 Now $11.12 −0.00% ▲ +7.46% +8.46% vs SPY
  7. Aug 15, 202613w ago Institutional Cluster Bearish 6/10 Entry $11.20 to $12.46 Now $11.12 +0.71% ▼ −11.25% −14.19% vs SPY
  8. Aug 11, 202613w ago 424B5 Bearish 7/10 Entry $10.36 to $11.13 Now $11.12 −7.39% ▼ −7.48% −12.60% vs SPY
  9. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $9.34 to $12.18 Now $11.12 +19.06% ▲ +30.41% +32.82% vs SPY
  10. Jul 29, 202615w ago 8-K Bullish 6/10 Entry $5.39 to $11.37 Now $11.12 +106.31% ▲ +110.95% +106.22% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 8h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026